Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O’Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen - Chief Scientific Officer Michelle LaSpaluto - Chief Financial Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earni ...

Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.23 per share when it actually produced a loss of $0.23, delivering no surprise.Over the last four quarters, the company has surpas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdictio ...

Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update – Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., November 7, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical compan ...

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307- ...

DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c) (4). ...

Chimerix, Inc. (NASDAQ:CMRX) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O’Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Officer Michelle LaSpaluto - Chief Financial Officer Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Soumit Roy - Jones Research Ed White - HC Wainwright Troy Langford - TD Cowen Op ...

Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Chimerix, which belongs to ...

Part I [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Chimerix, Inc.'s unaudited consolidated financial statements for H1 2024 report a **$42.6 million** net loss and decreased assets [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $15,658 | $27,661 | | Total current assets | $153,455 | $189,110 | | Total assets | $178,511 | $212,774 | | Total current liabilities | $22,102 | $18,443 | | Total liabilities | $22,929 | $19,745 | | Total stockholders' equity | $155,582 | $193,029 | [Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Statement of Operations Summary (in thousands) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $129 | $26 | $129 | $309 | | Research and development | $18,428 | $16,926 | $37,272 | $35,748 | | General and administrative | $4,533 | $4,448 | $10,079 | $10,127 | | Loss from operations | $(22,832) | $(21,348) | $(47,222) | $(45,566) | | Net loss | $(20,685) | $(18,576) | $(42,554) | $(39,948) | | Net loss per share | $(0.23) | $(0.21) | $(0.48) | $(0.45) | [Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Consolidated%20Statements%20of%20Stockholders'%20Equity) - Total stockholders' equity decreased from **$193.0 million** at December 31, 2023, to **$155.6 million** at June 30, 2024, primarily due to a net loss of **$42.6 million** for the six-month period, partially offset by **$4.9 million** in share-based compensation[10](index=10&type=chunk)[12](index=12&type=chunk) [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary for Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | $(35,201) | $(36,567) | | Net cash provided by investing activities | $23,032 | $30,656 | | Net cash provided by financing activities | $166 | $168 | | Net decrease in cash and cash equivalents | $(12,003) | $(5,743) | | Cash and cash equivalents, end of period | $15,658 | $20,099 | [Notes to the Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Consolidated%20Financial%20Statements) - Chimerix is a biopharmaceutical company focused on developing imipridones as cancer therapies, with its lead candidate dordaviprone (ONC201) in clinical development for H3 K27M-mutant diffuse glioma[16](index=16&type=chunk) - On June 27, 2024, the company received a notice from Nasdaq for non-compliance with the minimum bid price rule ($1.00 per share) and has until December 24, 2024, to regain compliance[39](index=39&type=chunk)[40](index=40&type=chunk) - In February 2024, Chimerix established an At-The-Market (ATM) equity offering agreement to sell up to **$75 million** of its common stock, with no sales made as of June 30, 2024[57](index=57&type=chunk) - The company is eligible for up to **$124 million** in milestone payments and tiered royalties from Emergent BioSolutions related to the 2022 sale of TEMBEXA[29](index=29&type=chunk)[67](index=67&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses dordaviprone's clinical progress and reports a **$42.6 million** net loss for H1 2024, affirming sufficient capital for the next 12 months - The Phase 3 ACTION trial for dordaviprone is enrolling patients across 13 countries, with interim overall survival (OS) data expected in Q3 2025, and the company is also pursuing a Provisional Registration pathway in Australia[77](index=77&type=chunk)[79](index=79&type=chunk) Results of Operations Comparison (in thousands) | Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | | Total Revenues | $129 | $309 | | Research & Development Expenses | $37,272 | $35,748 | | General & Administrative Expenses | $10,079 | $10,127 | | Net Loss | $(42,554) | $(39,948) | - As of June 30, 2024, Chimerix had approximately **$171.5 million** in available capital, which is believed to be sufficient to fund operations and capital requirements for at least the next 12 months[113](index=113&type=chunk)[117](index=117&type=chunk) - Net cash used in operating activities was **$35.2 million** for the first six months of 2024, a slight decrease from **$36.6 million** in the same period of 2023[119](index=119&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=28&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its short-term investment portfolio, with no material impact expected from rate changes or inflation - The company's main market risk is interest income sensitivity, affected by U.S. interest rate changes[129](index=129&type=chunk) - Due to the short-term, low-risk nature of its investment portfolio, an immediate **10%** change in interest rates is not expected to have a material effect on the company's financial condition[129](index=129&type=chunk) - Inflation is not believed to have had a material effect on the results of operations for the reported periods[130](index=130&type=chunk) [Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures) The company's disclosure controls and procedures were deemed effective as of June 30, 2024, with no material changes to internal control over financial reporting during Q2 2024 - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the period, June 30, 2024[131](index=131&type=chunk) - There were no changes in internal control over financial reporting during the second quarter of 2024 that have materially affected, or are reasonably likely to materially affect, these controls[132](index=132&type=chunk) Part II [Legal Proceedings](index=29&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that there were no material legal proceedings during the reporting period - The company reports "None"[134](index=134&type=chunk) [Risk Factors](index=29&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including historical losses, product development uncertainty, reliance on third parties, potential Nasdaq delisting, competition, and intellectual property and data privacy concerns - The company has a history of significant losses, with an accumulated deficit of approximately **$838.1 million** as of June 30, 2024, and anticipates incurring future losses[136](index=136&type=chunk)[138](index=138&type=chunk) - All product candidates are in clinical development and may not obtain regulatory approval or be successfully commercialized, making the success of the lead candidate, dordaviprone, critical[136](index=136&type=chunk)[156](index=156&type=chunk) - The company's common stock is at risk of being delisted from The Nasdaq Global Market for failing to maintain a minimum bid price of **$1.00** per share, which could negatively impact its price and liquidity[136](index=136&type=chunk)[251](index=251&type=chunk)[252](index=252&type=chunk) - The company relies on third-party manufacturers for drug supply and CROs for clinical trials, creating risks related to supply disruption, quality control, and regulatory compliance[136](index=136&type=chunk)[193](index=193&type=chunk)[201](index=201&type=chunk) - The company is subject to stringent data privacy and security laws (e.g., GDPR, CCPA), where a failure to comply or a data breach could result in significant fines, litigation, and reputational harm[272](index=272&type=chunk)[283](index=283&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=56&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports that there were no unregistered sales of equity securities during the period - The company reports "None"[295](index=295&type=chunk) [Defaults Upon Senior Securities](index=56&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports that there were no defaults upon senior securities - The company reports "None"[295](index=295&type=chunk) [Mine Safety Disclosures](index=56&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's business - The company reports "Not applicable"[295](index=295&type=chunk) [Other Information](index=57&type=section&id=Item%205.%20Other%20Information) The company reports no other material information for the period, including any trading arrangements by directors or officers - The company reports no trading arrangements[296](index=296&type=chunk) [Exhibits](index=58&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the quarterly report, including corporate governance documents, equity award agreements, and required officer certifications - The report includes exhibits such as the Chimerix, Inc. 2024 Equity Incentive Plan, forms of stock option and RSU agreements, and officer certifications required under the Securities Exchange Act of 1934[298](index=298&type=chunk) Signatures - The report was duly signed on August 13, 2024, by Michael T. Andriole, President and Chief Executive Officer, and Michelle LaSpaluto, Chief Financial Officer[302](index=302&type=chunk)

Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods Administration in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., August 13, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASD ...